Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase IV, multicenter, randomized, double blind clinical trial. The investigators will study 48 patients with remitting relapsing multiple sclerosis (MS) experiencing moderate or severe attack receiving immunomodulatory therapy or not. Patients will be randomly assigned to one of the two groups.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Germans Trias i Pujol Hospital
• Treatments: Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

1. To have been diagnosed MS Remittent Recurrent according to Mc Donald 20052 criteria.

2. To have an EDSS between 0 and 5 before the relapse.

3. The symptoms have begun after at least one month of previous stability.

4. The symptoms have started maximum 15 days before the inclusion.

5. The patient is capable of having an adequate communication with the investigator and to carry out with the clinical trial requisites.

6. To be or not to be with allowed immunomodulatory therapy (IFN-B /AG).

7. To be capable and to be willing to ingest the medication.

Exclusion Criteria:

1. First inflammatory neurological episode (relapse).

2. Multiple sclerosis secondary progressive or primary progressive.

3. The symptoms have gone on for less than 24 hours.

4. To be in treatment or have been treated with corticoids during the three months before.

5. Patients in treatment with immunosuppressors (azathioprine, mitoxantrone, ciclofosfamide...)

6. Pregnancy or breastfeeding or women in fertile age who don't use contraceptives measurements.

7. Illnesses with contraindication treatment with corticoids.

8. Antecedents of serious adverse effects or hypersensitive to related study medication.

9. Patients who wouldn´t be able to perform periodic RMN explorations, patients who are not collaborative or who need anesthesia.

10. Patients with intolerance to lactose.

11. Patients with allergy to contrast used in RMN.

12. Patients with chronic kidney disease.

13. Patients in treatment with natalizumab.